Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.

Trial Profile

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Heparin; Low molecular weight heparins; Rivaroxaban; Vitamin K antagonists
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EINSTEIN-DVT-dose-finding
  • Sponsors Bayer
  • Most Recent Events

    • 08 May 2009 Additional lead trial centres identified as reported by as reported by Australian New Zealand Clinical Trials Registry record.
    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry, record no.ACTRN12605000597695).
    • 15 Sep 2008 Results were published in Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top